Citrate anticoagulation for continuous renal replacement therapy in the critically ill

Blood Purification

Volumn 29, Issue 2, 2010, Pages 191-196

  Oudemans Van Straaten, Heleen M ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Anticoagulation; Biocompatibility; Citrate; Hemodialysis; Hemofiltration; Hemorrhage; Heparin; Organ failure; Sepsis; Survival

Indexed keywords

CALCIUM ION; CITRIC ACID; NADROPARIN;

ACID BASE BALANCE; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; HUMAN; MEDICAL LITERATURE; METABOLIC ACIDOSIS; METABOLIC REGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOSIS PREVENTION;

ACID-BASE IMBALANCE; AGED; ANTICOAGULANTS; BUFFERS; CITRIC ACID; CITRIC ACID CYCLE; CLINICAL PROTOCOLS; CRITICAL ILLNESS; EQUIPMENT FAILURE; FEASIBILITY STUDIES; HEMORRHAGE; HEPARIN; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL REPLACEMENT THERAPY; SEPSIS; SURVIVAL ANALYSIS; WATER-ELECTROLYTE IMBALANCE;

EID: 77749318468     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245646     Document Type: Article

References (26)

1. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265.
2. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367.
3. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20: 602-608.
4. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552.
5. Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981.
6. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR: Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202.
7. Chadha V, Garg U, Warady BA, Alon US: Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 2002; 17: 819-824.
8. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A: Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997; 109: 123-127.
9. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455.
10. Meier-Kriesche HU, Gitomer J, Finkel K, Du Bose T: Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752.
11. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH: Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med 2006; 44: 962-966.
12. Joannidis M, Oudemans-van Straaten HM: Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218.
13. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7: 234-241.
14. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ: Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387-1393.
15. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C: The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17: 819-825.
16. Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nube MJ: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159.
17. Bohler J, Donauer J, Birmelin M, Schollmeyer PJ, Horl WH: Mediators of complementindependent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes. Nephrol Dial Transplant 1993; 8: 1359-1365.
18. 2+ influx across the plasma membrane of human neutrophils. Mol Pharmacol 1986; 30: 437-443.
19. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M: Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. Nephrol Dial Transplant 2000; 15: 1631-1637.
20. Gritters M, Borgdorff P, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Tangelder GJ, Nube MJ: Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility? Nephrol Dial Transplant 2008; 23: 2911-2917.
21. Borawski J: Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis 2006; 47: 37-41.
22. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD: Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-252.
23. Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ: Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003; 90: 1150-1157.
24. Cornet AD, Smit EG, Beishuizen A, Groeneveld AB: The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98: 579-586.
25. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I: Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000; 97: 2826-2831.
26. Feldkamp T, Weinberg JM, Horbelt M, Von Kropff C, Witzke O, Nurnberger J, Kribben A: Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation. Nephrol Dial Transplant 2009; 24: 43-51.